专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080075768A1 HYDROPHOBIC OPIOID ABUSE DETERRENT DELIVERY SYSTEM USING OPIOID ANTAGONISTS 审中-公开
标题翻译：使用OPIOID ANTAGONISTS的HYDROPHOBIC OPIOID ABUSE DETERRENT DELIVERY SYSTEM
公开(公告)号：US20080075768A1
公开(公告)日：2008-03-27
申请号：US11781044
申请日：2007-07-20
申请人： Jason Vaughn , Michael Crowley , Feng Zhang , John Koleng , Justin Keen , Justin Hughey
发明人： Jason Vaughn , Michael Crowley , Feng Zhang , John Koleng , Justin Keen , Justin Hughey
IPC分类号： A61K9/48 , A61K47/12 , A61K47/38 , A61P25/36 , A61K9/00
CPC分类号： A61K9/2027 , A61K9/2013 , A61K9/2054 , Y02A50/411
摘要： Disclosed herein are oral dosage forms of opioid therapeutic agents that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution in aqueous solutions of ethanol are described. The oral dosage forms may include one or more opioid antagonists that are sequestered from the opioid therapeutic agent such that the opioid antagonist has no substantial effect on the activity of the opioid therapeutic agent when the dosage form is taken orally as prescribed, but the opioid antagonist is released in an amount that reduces the effectiveness of the opioid therapeutic agent contained in the dosage form when the dosage form is crushed.
摘要翻译：本文公开了耐滥用的阿片样物质治疗剂的口服剂型及其制剂方法。特别地，描述了耐溶于乙醇水溶液的口服剂型。口服剂型可以包括一种或多种从阿片样物质治疗剂螯合的阿片样物质拮抗剂，使得阿片样物质拮抗剂在剂型按规定口服给药时对阿片样物质治疗药物的活性没有显着影响，但阿片样物质拮抗剂释放的量可以降低当剂型被粉碎时所述剂型中所含的阿片样物质治疗剂的有效性。

2. 发明申请

US20080069871A1 HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM 审中-公开
标题翻译：疏水性废物输送系统
公开(公告)号：US20080069871A1
公开(公告)日：2008-03-20
申请号：US11781008
申请日：2007-07-20
申请人： Jason Vaughn , Michael Crowley , Feng Zhang , John Koleng , Justin Keen , Justin Hughey
发明人： Jason Vaughn , Michael Crowley , Feng Zhang , John Koleng , Justin Keen , Justin Hughey
IPC分类号： A61K47/30 , A61K47/38 , A61K9/14 , A61K9/52 , A61P25/04
CPC分类号： A61K9/2027 , A61K9/2013 , A61K9/2054 , Y02A50/411
摘要： Disclosed herein are oral dosage forms of therapeutic agents that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution in aqueous solutions of ethanol are described.
摘要翻译：本文公开了耐滥用的治疗剂的口服剂型及其制剂的方法。特别地，描述了耐溶于乙醇水溶液的口服剂型。

3. 发明申请

US20110021588A1 SUBLINGUAL DEXMEDITOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF 审中-公开
标题翻译：次甲基吡啶组合物及其使用方法
公开(公告)号：US20110021588A1
公开(公告)日：2011-01-27
申请号：US12781628
申请日：2010-05-17
申请人： Geraldine Anne Henwood , Randall Jerome Mack , Christopher T. Sharr , John Koleng
发明人： Geraldine Anne Henwood , Randall Jerome Mack , Christopher T. Sharr , John Koleng
IPC分类号： A61K31/4174 , A61P29/00
CPC分类号： A61K9/006 , A61K9/08 , A61K31/4174 , A61K47/32 , A61P29/00
摘要： Analgesic sublingual formulations of dexmedetomidine and methods of use thereof are provided for use in the prevention, treatment and management of pain and other conditions.
摘要翻译：提供右美托咪定的镇痛舌下制剂及其使用方法，用于预防，治疗和治疗疼痛及其他病症。

4. 发明申请

US20080020032A1 HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM FOR HYDROMORPHONE 审中-公开
标题翻译：用于氢键的疏水性消毒剂输送系统
公开(公告)号：US20080020032A1
公开(公告)日：2008-01-24
申请号：US11781088
申请日：2007-07-20
申请人： Michael Crowley , Feng Zhang , John Koleng , Justin Keen , Jason Vaughn , Justin Hughey
发明人： Michael Crowley , Feng Zhang , John Koleng , Justin Keen , Jason Vaughn , Justin Hughey
IPC分类号： A61K31/4355 , A61K9/48
CPC分类号： A61K9/2027 , A61K9/2013 , A61K9/2054 , Y02A50/411
摘要： Disclosed herein are oral dosage forms of hydromorphone that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution in aqueous solutions of ethanol are described.
摘要翻译：本文公开了耐受滥用的氢吗啡酮的口服剂型及其制剂方法。特别地，描述了耐溶于乙醇水溶液的口服剂型。

5. 发明申请

US20060193908A1 Extended release formulations of poorly soluble antibiotics 审中-公开
标题翻译：难溶性抗生素的延长释放制剂
公开(公告)号：US20060193908A1
公开(公告)日：2006-08-31
申请号：US11267943
申请日：2005-11-04
申请人： Beth Burnside , Colin Rowlings , Sandra Wassink , Donald Treacy , John Koleng
发明人： Beth Burnside , Colin Rowlings , Sandra Wassink , Donald Treacy , John Koleng
IPC分类号： A61K31/7048 , A61K9/20
CPC分类号： A61K9/2077 , A61K9/2009 , A61K9/2018 , A61K31/7048
摘要： An extended release pharmaceutical compressed composition and dosage form comprising poorly water soluble macrolide antibiotic, surfactant and non-lipophilic, non-polymeric excipient is disclosed. The composition releases the macrolide antibiotic over an extended period of time, generally at least over 12 hours, even in the absence of a release rate-retarding polymer, release rate-retarding coating or release rate-retarding lipophilic excipient. The composition is suitable for once daily or twice daily oral administration for the treatment of many different types of bacterial infections. One embodiment of the compressed composition includes a drug-containing granular composition and a binding composition, wherein the two are mixed together and then compressed into a tablet or pill. The surfactant is in admixture with or coated onto the macrolide antibiotic, and it can be included in the granular composition and/or the binding composition. The non-polymeric, non-lipophilic excipient is included in the granular composition and/or the binding composition.
摘要翻译：公开了包含难溶于水的大环内酯类抗生素，表面活性剂和非亲脂性非聚合物赋形剂的延长释放药物压缩组合物和剂型。即使在没有释放速率阻滞性聚合物，释放速率阻滞涂层或释放速率延缓的亲脂性赋形剂的情况下，该组合物延长的时间段（通常至少超过12小时）释放大环内酯类抗生素。该组合物适合于每天一次或每天两次口服给药以治疗许多不同类型的细菌感染。压缩组合物的一个实施方案包括含药物的颗粒组合物和结合组合物，其中两者混合在一起，然后压制成片剂或药丸。表面活性剂与大环内酯类抗生素混合或涂覆在其上，并且可以包含在颗粒组合物和/或粘合组合物中。非聚合的非亲脂性赋形剂包括在颗粒组合物和/或粘合组合物中。

6. 发明申请

US20050220865A1 Compressed composition comprising magnesium salt 审中-公开
标题翻译：包含镁盐的压缩组合物
公开(公告)号：US20050220865A1
公开(公告)日：2005-10-06
申请号：US10816771
申请日：2004-04-02
申请人： John Koleng , Michael Crowley
发明人： John Koleng , Michael Crowley
IPC分类号： A61K9/20 , A61K9/48 , A61K33/06 , A61K33/08 , A61K33/10
CPC分类号： A61K9/2095 , A61K9/2054 , A61K9/2077 , A61K33/06 , A61K33/08 , A61K33/10
摘要： An oral solid compress composition comprising a magnesium salt is provided. The composition provides a rapid dissolution of the magnesium salt, wherein not less than 75% of the magnesium salt dissolves within 45 minutes after placement in hydrochloric acid (0.1 N, 900 mL) as per USP Method . In a particular embodiment, the magnesium salt is an inorganic salt such as MgO, Mg(OH)2, MgCl2, and others. The composition can be prepared by dry granulation, direct compression or another suitable process. The composition provides a substantially stable dissolution profile for the magnesium salt so that the dissolution profile changes only minimally even after an extended period of storage under pharmaceutically acceptable conditions when packaged in a sealed container-enclosure system. The solid composition may also exclude a cellulose-based composition. The compressed composition can be prepared and stored under anhydrous conditions.
摘要翻译：提供包含镁盐的口服固体压片组合物。该组合物提供镁盐的快速溶解，其中不少于75％的镁盐在按照USP Method <711>放入盐酸（0.1N，900mL）后45分钟内溶解。在一个具体实施方案中，镁盐是无机盐，例如MgO，Mg（OH）2，MgCl 2等。组合物可以通过干法制粒，直接压片或其它合适的方法制备。组合物为镁盐提供基本上稳定的溶出曲线，使得即使在包装在密封的容器 - 包封系统中的药学上可接受的条件下长时间的储存后，溶出曲线也仅最小化。固体组合物还可以排除基于纤维素的组合物。压缩的组合物可以在无水条件下制备并储存。

7. 发明申请

US20100047345A1 HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM FOR HYDROMORPHONE 审中-公开
标题翻译：用于氢键的疏水性消毒剂输送系统
公开(公告)号：US20100047345A1
公开(公告)日：2010-02-25
申请号：US12612511
申请日：2009-11-04
申请人： Michael M. Crowley , Feng Zhang , John Koleng , Justin Keen , Jason Vaughn , Justin Hughey
发明人： Michael M. Crowley , Feng Zhang , John Koleng , Justin Keen , Jason Vaughn , Justin Hughey
IPC分类号： A61K9/22 , A61K31/485
CPC分类号： A61K9/2027 , A61K9/2013 , A61K9/2054 , Y02A50/411
摘要： Disclosed herein are oral dosage forms of hydromorphone that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution in aqueous solutions of ethanol are described.
摘要翻译：本文公开了耐受滥用的氢吗啡酮的口服剂型及其制剂方法。特别地，描述了耐溶于乙醇水溶液的口服剂型。

8. 发明申请

US20080075771A1 HYDROPHILIC OPIOID ABUSE DETERRENT DELIVERY SYSTEM USING OPIOID ANTAGONISTS 审中-公开
标题翻译：使用OPIOID ANTAGONISTS的水解阿片类药物免疫传递系统
公开(公告)号：US20080075771A1
公开(公告)日：2008-03-27
申请号：US11781050
申请日：2007-07-20
申请人： Jason Vaughn , Michael Crowley , Feng Zhang , John Koleng , Justin Keen , Justin Hughey
发明人： Jason Vaughn , Michael Crowley , Feng Zhang , John Koleng , Justin Keen , Justin Hughey
IPC分类号： A61K31/34 , A61K9/56 , A61P25/04
CPC分类号： A61K9/2027 , A61K9/2013 , A61K9/2054 , Y02A50/411
摘要： Disclosed herein are oral dosage forms of opioid therapeutic agents that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution in aqueous solutions of ethanol are described. The oral dosage forms may include one or more opioid antagonists that are sequestered from the opioid therapeutic agent such that the opioid antagonist has no substantial effect on the activity of the opioid therapeutic agent when the dosage form is taken orally as prescribed, but the opioid antagonist is released in an amount that reduces the effectiveness of the opioid therapeutic agent contained in the dosage form when the dosage form is crushed.
摘要翻译：本文公开了耐滥用的阿片样物质治疗剂的口服剂型及其制剂方法。特别地，描述了耐溶于乙醇水溶液的口服剂型。口服剂型可以包括一种或多种从阿片样物质治疗剂螯合的阿片样物质拮抗剂，使得阿片样物质拮抗剂在剂型按规定口服给药时对阿片样物质治疗药物的活性没有显着影响，但阿片样物质拮抗剂释放的量可以降低当剂型被粉碎时所述剂型中所含的阿片样物质治疗剂的有效性。

9. 发明申请

US20080075770A1 HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM 审中-公开
标题翻译：水IC USE USE ENT ENT。。。。。。。。
公开(公告)号：US20080075770A1
公开(公告)日：2008-03-27
申请号：US11781032
申请日：2007-07-20
申请人： Jason Vaughn , Michael Crowley , Feng Zhang , John Koleng , Justin Keen , Justin Hughey
发明人： Jason Vaughn , Michael Crowley , Feng Zhang , John Koleng , Justin Keen , Justin Hughey
IPC分类号： A61K9/56 , A61K31/34 , A61P25/04
CPC分类号： A61K9/2027 , A61K9/2013 , A61K9/2054 , Y02A50/411
摘要： Disclosed herein are oral dosage forms of therapeutic agents that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution in aqueous solutions of ethanol are described.
摘要翻译：本文公开了耐滥用的治疗剂的口服剂型及其制剂方法。特别地，描述了耐溶于乙醇水溶液的口服剂型。

10. 发明申请

US20120231083A1 SUSTAINED RELEASE CANNABINOID MEDICAMENTS 审中-公开
标题翻译：持续释放CANNABINOID药物
公开(公告)号：US20120231083A1
公开(公告)日：2012-09-13
申请号：US13474666
申请日：2012-05-17
申请人： David Carley , Kenton Fedde , John KOLENG , Peter LETENDRE
发明人： David Carley , Kenton Fedde , John KOLENG , Peter LETENDRE
IPC分类号： A61K9/14 , A61P11/00 , A61K31/352
CPC分类号： A61K31/352 , A61K9/0095 , A61K9/146 , A61K9/1611 , A61K9/1652 , A61K9/2009 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2077 , A61K9/2086 , A61K9/209 , A61K9/2095 , A61K9/284 , A61K9/2846 , A61K9/2886 , A61K9/4891 , A61K9/5026 , A61K9/5042 , A61K9/5084 , A61K47/10 , A61K47/38
摘要： The present invention provides a medicament which results in delivery of a therapeutic level of one or more cannabinoids during a clinically relevant therapeutic window. The therapeutic window is a longer window than provided by an immediate release medicament such as Marinol containing an equivalent amount of the cannabinoid. Oral administration of the present compositions provides therapeutic dosing while maintaining safe, side effect sparing, levels of a cannabinoid. The present invention also provides methods of treating cannabinoid-sensitive disorders.
摘要翻译：本发明提供一种在临床相关的治疗窗口中导致一种或多种大麻素的治疗水平递送的药物。治疗窗是比立即释放药物提供的更长的窗口，例如含有等量的大麻素的马林醇。口服给药本发明组合物提供治疗剂量，同时维持安全的副作用，大麻素水平。本发明还提供了治疗大麻素敏感性疾病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式